title: Preserving future therapeutic options:  should we limit the lamivudine use in young HIV-1 infected children initiating first-line HAART?
authors.affiliation: Unité d'Immunologie, Hématologie et Rhumatologie pédiatriques, AP-HP, Hôpital Necker - Enfants malades bEA3620, Paris, France. pierre.frange@nck.aphp.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Frange
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Chaix
authors.forename: Stephane
authors.initials: S
authors.lastname: Blanche
mesh_terms: D000367:Age Factors; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D007223:Infant; D019259:Lamivudine / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D019259:Lamivudine